These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis. Thachil J Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488 [TBL] [Abstract][Full Text] [Related]
3. Pentasaccharides. The new anticoagulants. Abdel-Razeq H Saudi Med J; 2004 Aug; 25(8):983-90. PubMed ID: 15322584 [TBL] [Abstract][Full Text] [Related]
4. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery. Tran AH; Lee G Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815 [TBL] [Abstract][Full Text] [Related]
5. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism. Robinson DM; Wellington K Am J Cardiovasc Drugs; 2005; 5(5):335-46. PubMed ID: 16156690 [TBL] [Abstract][Full Text] [Related]
6. The safety of fondaparinux sodium for the treatment of venous thromboembolism. Mastroiacovo D; Sala G; Dentali F Expert Opin Drug Saf; 2016 Sep; 15(9):1259-65. PubMed ID: 27537418 [TBL] [Abstract][Full Text] [Related]
7. Fondaparinux: an update on new study results. Bauersachs RM Eur J Clin Invest; 2005 Mar; 35 Suppl 1():27-32. PubMed ID: 15701145 [TBL] [Abstract][Full Text] [Related]
8. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery. Colwell C; Mouret P Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914 [TBL] [Abstract][Full Text] [Related]
9. Anticoagulation via anti-Factor Xa inhibition. Wiles N; Hunt BJ Lupus; 2006; 15(3):167-71. PubMed ID: 16634371 [TBL] [Abstract][Full Text] [Related]
10. The pharmacoeconomics of deep vein thrombosis treatment. Shorr AF Am J Med; 2007 Oct; 120(10 Suppl 2):S35-41. PubMed ID: 17916458 [TBL] [Abstract][Full Text] [Related]
12. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Turpie AG Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449 [TBL] [Abstract][Full Text] [Related]
13. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487 [TBL] [Abstract][Full Text] [Related]
14. From heparins to factor Xa inhibitors and beyond. Alban S Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143 [TBL] [Abstract][Full Text] [Related]
15. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Bauer KA Best Pract Res Clin Haematol; 2004 Mar; 17(1):89-104. PubMed ID: 15171960 [TBL] [Abstract][Full Text] [Related]
16. Fondaparinux (Arixtra): a new anticoagulant. Giangrande PL Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373 [TBL] [Abstract][Full Text] [Related]
17. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. Bauer KA Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577 [TBL] [Abstract][Full Text] [Related]
18. Fondaparinux: use in thromboprophylaxis of acute medical patients. Dhillon S; Plosker GL Drugs Aging; 2008; 25(1):81-8. PubMed ID: 18184032 [TBL] [Abstract][Full Text] [Related]
19. Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors. Nutescu EA; Helgason CM Pharmacotherapy; 2004 Jul; 24(7 Pt 2):82S-87S. PubMed ID: 15317403 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Samama MM; Gerotziafas GT Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]